An interventional study of ARC-IM Investigational System in Hypotension Symptomatic, Parkinson's Disease and Orthostatic Hypotension, Dysautonomic, sponsored by Ecole Polytechnique Fédérale de Lausanne. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.
Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 61st largest by planned enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 49 with no phase, reaches primary completion later than 33 of the 33 other live ones, and was the 74th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–75
Siegward -M. Elsas · Sites in Switzerland
Ages 50–79
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Alain Kaelin · Sites in Switzerland
Ages 50–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 30 across the 67 interventional studies, 64 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 85 have an industry lead sponsor. The 10 most frequent:
Ecole Polytechnique Fédérale de Lausanne is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Ecole Polytechnique Fédérale de Lausanne has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Parkinson Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831500Julien BallyFeasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | 2026-11 |
| NCT07485218University of Applied Sciences and Arts of Southern SwitzerlandMultidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's Disease | 2026-12 |
| NCT06608875University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT05765110Insel Gruppe AG, University Hospital BernSPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease | 2026-12-31 |
| NCT07802509Klinik ValensDoes Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Parkinson Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be provided with the ARC-IM Investigational System (implantable and non-implan
Device: ARC-IM Investigational System
Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
Occurrence of (serious) adverse device effects of the ARC-IM Therapy from baseline up to the end of the study.
Evaluate the safety of ARC-IM Therapy in supporting hemodynamic management in participants with atypical or typical Parkinson's Disease and orthostatic hypotension
Time frame: Throughout the study (up to 5 years)
10-minute, orthostatic head-up tilt test with and without the ARC-IM Therapy at 1 month after intervention
Preliminary and long-term efficacy of the ARC-IM Therapy to reduce orthostatic hypotension. Measurement tool: Drop in blood pressure over time (mmHg and sec, mmHg/sec)
Time frame: At the end of, 6 months after and 1 year after configuration of the therapy,
Severity of symptoms measured by The Orthostatic Hypotension Questionnaire.
This outcome measures the preliminary long-term efficacy of the ARC-IM Therapy to support hemodynamic instability. The Orthostatic Hypotension Questionnaire (OHQ) has 10 hypotension symptom-related items rated on a 11 point scale (0 - 10). Measurement tool: 0 indicates no symptoms and 10 indicates worst possible severity/outcome. A higher total score indicates worse symptomatology.
Time frame: At the end of, 6 months after and 1 year after configuration of the therapy
Time Up and Go Test (TUG)
Preliminary efficacy of the ARC-IM Therapy to improve physical activity. The Time Up and Go will measure time from sit to stand and gait quality. Measurement tool: time (sec)
Time frame: At the end of, 6 months after and 1 year after configuration of the therapy
2 Minute Walk Test
Preliminary efficacy of the ARC-IM Therapy to improve physical activity. The 2 Minute Walk Test (2MWT) will measure gait endurance and distance walked over 2 minutes. Measurement tool: distance (meters)
Time frame: At the end of, 6 months after and 1 year after configuration of the therapy
Berg Balance Test
The Berg Balance Test measures the ability to balance safely with 14 specific tasks performed while standing, sitting, or making simple movements. The test scoring ranges from 0 to 56. Measurement tool: lower score indicates greater risk of losing your balance.
Time frame: At the end of, 6 months after and 1 year after configuration of the therapy
Quebec User Evaluation of Satisfaction with technology (QUEST 2.0)
To measure the usability of the ARC-IM Main Controller, Clinician Programmer, and Personal Programmer for clinicians and participants. The Quebec User Evaluation of Satisfaction with technology (QUEST 2.0) is a 12-item instrument that evaluates satisfaction with the therapy across form factor, safety, durability, simplicity of use, comfort, service of device and improvements. The evaluation will be performed by a moderator with the participant. Measurement tool: Total score from 12 to 60. Low score means a better outcome.
Time frame: At 6 months and 1 year after configuration of the therapy
System Usability Scale (SUS)
Assess the usability of the ARC-IM Main Controller, Clinician Programmer, and Personal Programmer for clinicians and participants. The System Usability Scale (SUS) is a 10-item scale that evaluates the usability and satisfaction of the technology. Measurement tool: Total score from 0 to 100. Higher score indicates better outcome.
Time frame: At 6 months and 1 year after configuration of the therapy
Additional user feedback of ARC-IM System
To assess the usability of the ARC-IM Main Controller, Clinician Programmer, and Personal Programmer for clinicians and participants. The Additional user feedback of ARC-IM System is a custom-made user feedback questionnaire to evaluate the overall satisfaction of specific aspects of the therapy including battery life, device communication etc. Measurement tool: Total score where applicable (higher score indicates better outcome) and feedback from participants
Time frame: At 6 months and 1 year after configuration of the therapy
Doppler ultrasound to measure cerebral blood perfusion with and without the ARC-IM Therapy
Time frame: 1 month, 6 months and 12 months post-therapy configuration
Supine hypertension will be evaluated during orthostatic tilt tests without the ARC-IM Therapy
Measurement tool: blood pressure (mmHg) during supine position of orthostatic tilt test
Time frame: 1 month, 6 months and 12 months post-therapy configuration
MDS-sponsored Unified Parkinson's Disease Rating Scale Part IB & II
Participants' quality of life will be assessed with MDS-sponsored Unified Parkinson's Disease Rating Scale Part IB \& II to measure sleep, mental health, and fatigue (MDS-UPDRS-IB \& II) over 20 items. Measurement tool: Total score (0 - 4 rating per question), 0 represents no impairment and 4 represents severe impairment. Higher total score indicates worse symptoms.
Time frame: 1 month, 6 months and 12 months post-therapy configuration
King's Parkinson's Disease Pain Scale
Participants' quality of life will be assessed with the 7-item King's Parkinson's Disease Pain Scale to characterize severity and types of pain associated with Parkinson's Disease. Measurement tool: Total score from 0 to 168. Lower score indicates a better outcome.
Time frame: 1 month, 6 months and 12 months post-therapy configuration
Parkinson's Disease Questionnaire-39 (PDQ-39)
Participants' quality of life will be measured by the 39 item Parkinson's Disease Questionnaire-39 (PDQ-39) to evaluate perceived health in terms of physical, mental and social functions. Measurement tool: Total score from 0-100, higher scores reflect lower quality of life
Time frame: 1 month, 6 months and 12 months post-therapy configuration
Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction
Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction (SCOPA-AUT) is a 25-item, self-completed questionnaire to evaluate autonomic symptoms in people with typical and atypical Parkinson's Disease. Measurement tool: Total score from 0-69 where a higher score indicates increased frequency of autonomic dysfunction symptoms
Time frame: 1 month, 6 months and 12 months post-therapy configuration
MDS sponsored Unified Parkinson's Disease Rating Scale Part III
Participants' quality of life will be assessed with the MDS-sponsored Unified Parkinson's Disease Rating Scale Part III (19 items) to evaluate motor function. Measurement tool: Total score from 0 to 132. Low score means a better outcome.
Time frame: Baseline (before surgery), and 1 month, 6 months and 12 months post-therapy configuration
24 hour ambulatory measurements
Participant's quality of life will be evaluated with 24 hour blood pressure measurements with and without the therapy. Measurement tool: blood pressure (mmHg)
Time frame: Baseline (before surgery), and 1 month, 6 months and 12 months post-therapy configuration
Closed-loop stimulation on management of hemodynamics will be measured with the change in blood pressure during 10 minute, head up tilt tests.
Closed-loop stimulation will receive feedback from a blood pressure sensor to automatically adjust stimulation intensity. We will evaluate the effects of this stimulation on management of hemodynamics during configuration sessions with pre-configured stimulations, with closed-loop stimulation and without stimulation. The feasibility and effectiveness will be measured by the drop in blood pressure (mmHg) during 10 minute, orthostatic, head-up tilt tests.
Time frame: Post-operative configuration phases, through year 1 of the study
Time Up and Go Test across different therapeutic conditions
The complementarity of the ARC-IM Therapy with standard therapies (e.g LDopa) will be assessed over the trajectory of therapy intake with and without stimulation during configuration phases with the Time Up and Go will measure time from sit to stand and gait quality. Measurement tool: time (sec)
Time frame: Post-operative configuration phases, through year 1 of the study
2 Minute Walk Test across different therapeutic conditions
The complementarity of the ARC-IM Therapy with standard therapies (e.g LDopa) will be assessed over the trajectory of therapy intake with and without stimulation during configuration phases with the The 2 Minute Walk Test (2MWT) will measure gait endurance and distance walked over 2 minutes. Measurement tool: distance (meters)
Time frame: Post-operative configuration phases, through year 1 of the study
Berg Balance Test across different therapeutic conditions
The complementarity of the ARC-IM Therapy with standard therapies (e.g LDopa) will be assessed over the trajectory of therapy intake with and without stimulation during configuration phases with the Berg Balance Test measures the ability to balance safely with 14 specific tasks performed while standing, sitting, or making simple movements. Measurement tool: Total score from 0-56, lower score indicates greater risk of losing your balance.
Time frame: Post-operative configuration phases, through year 1 of the study
Montréal Cognitive Assessment (MoCA)
To objectively characterize and longitudinally monitor cognitive status over the course of the study, the Montréal Cognitive Assessment (MoCA) will be performed. This assessment evaluates several cognitive domains including attention, executive functions, memory, language, visuospatial abilities, abstraction, calculation and orientation. Measurement tool: Total score (0-30), with higher scores indicating better cognitive function.
Time frame: Baseline, 1 month, 6 months and 12 months post-therapy configuration
Started Jul 2025 (actual). Primary completion is estimated for May 2031, 69 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 69 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ecole Polytechnique Fédérale de Lausanne